αv Integrins as receptors for tumor targeting by circulating ligands
- 1 June 1997
- journal article
- Published by Springer Nature in Nature Biotechnology
- Vol. 15 (6), 542-546
- https://doi.org/10.1038/nbt0697-542
Abstract
Phage displaying an Arg-Gly-Asp (RGD)-containing peptide with a high affinity for alpha v integrins homed to tumors when injected intravenously into tumor-bearing mice. A substantially higher amount of alpha v-directed RGD phage than control phage was recovered from malignant melanomas and breast carcinoma. Antibodies detected the alpha v-directed RGD phage in tumor blood vessels, but not in several normal tissues. These results show that the alpha v integrins present in tumor blood vessels can bind circulating ligands and that RGD peptides selective for these integrins may be suitable tools in tumor targeting for diagnostic and therapeutic purposes.Keywords
This publication has 27 references indexed in Scilit:
- Organ targeting In vivo using phage display peptide librariesNature, 1996
- Lu-ECAM-1-mediated adhesion of melanoma cells to endothelium under conditions of flowInternational Journal of Cancer, 1996
- Tumor targeting through fibroblast growth factor receptorsSeminars in Cancer Biology, 1995
- Tumour vasculature - a potential therapeutic targetBritish Journal of Cancer, 1995
- Endothelial receptor tyrosine kinases involved in angiogenesis.The Journal of cell biology, 1995
- VEGF-mediated tumour angiogenesis: a new target for cancer therapyCurrent Opinion in Biotechnology, 1995
- Integrin αvβ3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vesselsCell, 1994
- Traffic signals for lymphocyte recirculation and leukocyte emigration: The multistep paradigmCell, 1994
- Vascular targeting—a new approach to the therapy of solid tumorsPharmacology & Therapeutics, 1994
- The Cellular Basis of Site-Specific Tumor MetastasisNew England Journal of Medicine, 1990